Safety of direct oral anticoagulants in patients with advanced liver disease

BACKGROUND & AIMS: While direct oral anticoagulants (DOACs) are increasingly used in patients with liver disease, safety data especially in advanced chronic liver disease (ACLD) are limited. METHODS: Liver disease patients receiving DOAC treatment (ACLD: n = 104; vascular liver disease: n = 29)...

Descripción completa

Detalles Bibliográficos
Autores principales: Semmler, Georg, Pomej, Katharina, Bauer, David J. M., Balcar, Lorenz, Simbrunner, Benedikt, Binter, Teresa, Hartl, Lukas, Becker, Jeannette, Pinter, Matthias, Quehenberger, Peter, Trauner, Michael, Mandorfer, Mattias, Lisman, Ton, Reiberger, Thomas, Scheiner, Bernhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Cirrhosis, Liver Failure and Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456813/
https://www.ncbi.nlm.nih.gov/pubmed/34152697
http://dx.doi.org/10.1111/liv.14992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456813/
https://www.ncbi.nlm.nih.gov/pubmed/34152697
http://dx.doi.org/10.1111/liv.14992

Ejemplares similares